<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53512">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01735331</url>
  </required_header>
  <id_info>
    <org_study_id>BEHGynObs-3</org_study_id>
    <nct_id>NCT01735331</nct_id>
  </id_info>
  <brief_title>Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss</brief_title>
  <official_title>Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bagcilar Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bagcilar Training and Research Hospital</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is determine vascular endothelial growth factor levels and
      angiogenesis/vascularity from hysteroscopic endometrial biopsies which taken from patients
      who has Recurrent Pregnancy Loss.The endometrial vascular endothelial growth factor levels
      will be measured by immunohistochemical staining methods due to office hysteroscopic
      endometrial biopsy after the menstruation at follicular phase of menstrual cycle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective,observational,single-center study.Ethical approval was obtained
      from the Institutional Review Board.This study will be completed 30 patients with Habitual
      Abortus.

      Endometrial vascular endothelial growth factor levels will be measured using Flk-1 / Kinase
      Domain Receptor / Vascular endothelial growth factor receptor-2, Ab-1 (Rabbit PAb), Vascular
      Endothelial Growth Factor (VEGF) Ab-7 (VG1), Cluster of Differentiation 34 (Endothelial Cell
      Marker) Ab-1 (QBEnd/10), Vascular endothelial growth factor receptor-1 (N-term) (FLT1)
      antibody kits. All assays will be performed according to the manufacturer's instructions.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The primary outcome measure of this study is to determine endometrial vascular endothelial growth factor levels in patient with  Recurrent Pregnancy Loss</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Recurrent Pregnancy Loss Without Current Pregnancy</condition>
  <arm_group>
    <arm_group_label>VEGF level</arm_group_label>
    <description>VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>Patients with Abnormal Uterine Bleeding</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The patients with  Recurrent Pregnancy Loss
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with  Recurrent Pregnancy Loss who accept to join the study.

        Exclusion Criteria:

          -  Patients whose age of &lt;18 and &gt;45

          -  Patients with have any pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TANER A. USTA, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bagcilar Training and Research Hospital,Istanbul,Turkey.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bagcilar Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 22, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular endothelial growth factor, Recurrent Pregnancy Loss</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitogens</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
